GlassScriptPhysician profile
Mohammad L Ahmed
NPI 1457358053
$2,699.78
in general payments reported to CMS, 2019-2025
31 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $616 · 2021: $366 · 2022: $387 · 2023: $244 · 2024: $347 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $428.92 | 2019-2025 | |
| Pfizer INC. | $278.21 | 2019-2024 | |
| Biotronik INC. | $235.22 | 2020-2025 | Acticor 7 Vr-T Dx |
| Janssen Pharmaceuticals, INC | $181.88 | 2019-2022 | |
| Medtronic Vascular, INC. | $171.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.97 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.78 | 2020-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $112.86 | 2022-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $107.35 | 2019-2024 | |
| Abiomed | $102.24 | 2025 | |
| Amgen INC. | $87.61 | 2019-2024 | Repatha |
| Regeneron Healthcare Solutions, INC. | $83.63 | 2019-2023 | Dupixent |
| Kiniksa Pharmaceuticals International, Plc | $74.56 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $69.46 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $62.70 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $61.97 | 2019-2021 | |
| Ge Healthcare | $57.65 | 2020 | |
| Philips North America LLC | $53.25 | 2022-2024 | (Cm9) Amb Mon & Diag Und |
| E.R. Squibb & Sons, L.L.C. | $41.72 | 2019-2021 | |
| Novo Nordisk INC | $36.14 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $22.94 | 2023 | |
| Genentech USA, INC. | $22.33 | 2025 | Venclexta |
| Astellas Pharma US INC | $21.23 | 2019 | |
| Lantheus Medical Imaging, INC. | $20.59 | 2021 | |
| Amarin Pharma, INC. | $19.87 | 2020 | |
| Esperion Therapeutics, INC. | $18.00 | 2023 | Nexletol |
| Tactile Systems Technology INC | $16.94 | 2023 | Flexitouch Plus, Entre Plus |
| Kiniksa Pharmaceuticals, LTD. | $16.85 | 2023 | Arcalyst |
| Irhythm Technologies, INC. | $14.00 | 2020 | |
| Boston Scientific Corporation | $14.00 | 2022 | |
| Atricure, INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.